MWVC
EVH icon

Morgens Waterfall Vintiadis & Co’s Evolent Health EVH Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-51,300
Closed -$913K – 62
2017
Q3 		$913K Buy
51,300
+12,200
+31% +$251K 0.77% 33
2017
Q2 		$991K Buy
+39,100
New +$940K 0.96% 34

Other funds holding EVH

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
FG
Formula Growth Montreal, Quebec, Canada $222M AUM 27.84% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's EVH Position: Q4 2017 in Review

Morgens Waterfall Vintiadis & Co sold out of Evolent Health (EVH) in Q4 2017, closing a stake of 51,300 shares — an estimated $913K sold.

Morgens Waterfall Vintiadis & Co first reported a position in EVH in Q2 2017 and held it in 2 quarters. The position peaked at $991K in Q2 2017. 156 funds tracked by Wall St. Rank hold EVH as of Q4 2017.

  • Morgens Waterfall Vintiadis & Co reported no remaining Evolent Health position as of Q4 2017 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 51,300 Evolent Health shares in Q4 2017, an estimated $913K.
  • Morgens Waterfall Vintiadis & Co first reported a position in Evolent Health in Q2 2017 and held it in 2 quarters.
  • Morgens Waterfall Vintiadis & Co's Evolent Health position peaked at $991K in Q2 2017.
  • 156 funds tracked by Wall St. Rank held Evolent Health as of Q4 2017.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q4 2017, filed 14 Feb 2018.